Two Phases, Two Skin Realities

Perimenopause — the transition phase, lasting on average four to eight years before the final menstrual period — is defined by volatility. Hormonal levels swing unpredictably rather than declining in a straight line.

These two environments create two distinct skin realities. Understanding which one applies to you changes how you approach treatment — and may save you months of trial and error with products that were never designed for your hormonal phase.

The Perimenopausal Skin Environment: Volatility as the Variable

Hormonal Fluctuation Drives Worse Acne Than Decline

One of the most counterintuitive findings in menopausal dermatology is that the transition phase, not the postmenopausal phase, tends to produce more severe and treatment-resistant acne. The reason lies in the nature of estrogen’s role in sebum regulation.

Estrogen does more than simply suppress androgen activity — it acts as a ballast, moderating the peaks and troughs of androgenic signalling the way a shock absorber moderates an uneven road. Remove the shock absorber and every bump registers fully. When estrogen is consistently low — as in postmenopause — sebaceous glands adapt, over time, to the new hormonal baseline. But when estrogen is erratically high one week and near-absent the next, the oil glands receive contradictory signals. The relative androgen excess that drives acne surges during estrogen troughs, then temporarily recedes when estrogen rises, only to surge again.

This produces acne with a distinctive character: unpredictable, cyclical in pattern even when cycles themselves have become irregular, and deeply frustrating to treat because what appeared to work during an estrogen-dominant week fails completely during an androgen-dominant one. The breakouts often cluster along the lower face — jawline, chin, perioral area — consistent with the androgen-dominant pattern, though their timing bears no obvious relationship to a regular cycle. This lower-face tendency should not be mistaken for a rule, however. In a prospective international study of 374 adult women, Dréno and colleagues found that nearly nine in ten had lesions distributed across multiple facial zones — cheeks, forehead, and temples as well as the jawline — while only about one in ten had acne confined to the mandibular area. The lower face is a frequent focus in perimenopause, but it is rarely the whole map.

If your skin seems to have a mind of its own — if nothing you do produces a consistent result — the volatility of perimenopausal hormones is very likely the reason. You are not doing something wrong. Your hormonal environment is shifting under you faster than any routine can follow.

The Perimenopausal Hormonal Timeline

What makes the perimenopausal hormonal profile particularly complex is that progesterone, not estrogen, typically declines first — a mechanism covered in detail in Article The Science of Menopausal Acne. The consequence for skin is an extended window, which can last years, in which progesterone’s mild anti-androgenic activity is already lost while estrogen remains partially active. Sebum quality shifts toward denser, more pore-clogging compositions.

The result is that a woman in her early-to-mid 40s may experience significant acne while her estrogen levels still appear within a normal premenopausal range. A clinical evaluation that captures hormonal status at only a single time point can therefore miss what is actually happening. In a cohort of women with treatment-resistant acne, was found that a fuller hormonal work-up frequently uncovered endocrine abnormalities that a single routine test would not.

What Perimenopausal Acne Looks Like

Location: Predominantly the lower third of the face — jawline, chin, perioral area, lower cheeks. This distribution reflects the higher androgen receptor density in this region and its greater sensitivity to hormonal fluctuation. The upper face (forehead, nose) is less commonly affected than in adolescent acne.

Lesion type: Predominantly inflammatory — papules, pustules, and nodules rather than the comedonal (blackhead and whitehead) pattern more common in teenage acne. Nodular and cystic lesions are common, particularly during estrogen-trough phases. These are the deep, painful, slow-healing breakouts that feel as though they are sitting under the skin — and that do not respond to surface-level treatments. These lesions originate deeper in the follicle, beyond the reach of most over-the-counter products.

Healing: Slower than in younger skin, and to a degree that research suggests is clinically meaningful. Reduced collagen synthesis and a hormonal component to cell turnover slowdown, which begins in early perimenopause rather than simply with age, mean that inflammatory lesions leave persistent red marks and pigmentation for weeks to months after the breakout itself resolves.

Predictability: Variable and often apparently random. Without a regular ovulatory cycle to anchor hormonal fluctuation, flares can occur at any point and do not follow a predictable pre-menstrual pattern.

The Postmenopausal Skin Environment: Persistence Without Volatility

A New Steady State

After the final menstrual period, the hormonal landscape settles. Estrogen drops to and remains at a consistently low level — typically below 20 pg/mL, a fraction of mid-cycle premenopausal levels, meaning estrogen’s role in moderating sebaceous gland activity effectively disappears. Progesterone approaches zero. Adrenal androgens — particularly DHEA-S (dehydroepiandrosterone sulfate), the primary androgen produced by the adrenal glands after ovarian function declines — decrease gradually with age but remain the predominant circulating sex steroids. In relative terms, the postmenopausal hormonal environment is therefore androgen-dominant.

For acne, this creates a counterintuitive situation: despite lower total androgens than in the premenopausal years, acne can persist, sometimes for decades, because the relative androgen signal, unchallenged by estrogen, is sufficient to maintain sebaceous gland stimulation. Think of it as a room where a quieter voice has always been there, but the louder voice that once drowned it out has left. The quiet voice hasn’t gotten louder; the room has simply gotten quieter around it. That persistent low-level acne at 57 — the kind you have gradually stopped expecting to resolve on its own, is this mechanism in practice. The shift from chaos to a stable baseline is not resolution; but it is the beginning of a more tractable treatment situation.

A 2025 systematic review by Telkkälä and colleagues, examining the causes of adult female acne, identified androgens as a central driver of the condition. Consistent with that mechanism, the absence of the perimenopausal storm does not eliminate the androgenic driver in postmenopause — it merely stabilises it.

Postmenopausal Acne: A Different Clinical Picture

Postmenopausal acne tends to differ from perimenopausal acne in several clinically meaningful ways:

Character: Less volatile, more consistently present. Women describe a steady low baseline of breakouts rather than dramatic flare-and-remission cycles. Because the acne does not resolve between episodes, cumulative scarring and post-inflammatory pigmentation accumulate in ways that the more acute perimenopausal phase may not have produced.

Skin context: The estrogen-depleted skin of postmenopause is typically thinner, drier, and more fragile than perimenopausal skin. Barrier function tends to be compromised as well. An observational study comparing postmenopausal women with women of reproductive age measured differences in transepidermal water loss and skin hydration consistent with reduced barrier integrity after menopause — assessed across general skin sites, not only where acne appears.

Treatment resistance: Postmenopausal acne can be particularly stubborn. The absence of estrogen means there is no native hormonal countermeasure buffering the androgenic signal. Women who have not responded to multiple courses of topical treatment, especially those with nodular or cystic presentation, may find that their clinician has fewer options available without hormonal or systemic intervention.

Hormonal treatment considerations: In postmenopause, hormone replacement therapy enters the picture differently than in perimenopause. The skin benefit of estrogen therapy, documented in improvements to ceramide levels, skin thickness, collagen content, and barrier function, is potentially greater where the estrogen deficit is absolute and stable. However, the choice of progestogen component in combined HRT matters significantly for acne: some progestins carry androgenic activity that can worsen the condition being treated.

No Single Test Resolves This

One of the frustrations of menopausal medicine is that there is no clean diagnostic test that reliably identifies which phase a woman is in. FSH (follicle-stimulating hormone) is commonly used as a menopausal marker — a sustained rise is taken as indicating the onset of ovarian insufficiency. But FSH fluctuates substantially during perimenopause, and a single elevated or normal reading provides limited information about where you currently sit hormonally — which is precisely the information your skin needs.

The practical answer to “which phase am I in?” is usually not a blood test alone — it is a combination of how your cycle has changed, what your skin is doing, and how long it has been doing it. Your own observations are not less valuable than a lab result here; in many cases, they are more informative.

A comprehensive hormonal evaluation for women with menopausal acne should include not only FSH and estradiol, but also testosterone (total and free), DHEA-S, LH, prolactin, and 17-hydroxyprogesterone — the last to help rule out adrenal causes of androgen excess that may co-exist with menopausal changes. This broad panel mirrors the work-up used by Ianoşi and colleagues in their study of treatment-resistant acne in women.

A Self-Assessment Guide

In practice, the distinction between the two phases is often most usefully made by combining any available hormonal data with your own observations. The following patterns are not diagnostic in isolation, and many women will recognise characteristics from both lists — particularly in the years immediately following the final menstrual period. But recognising where you broadly sit helps you and your clinician make better treatment decisions.

Patterns more consistent with active perimenopause: Your menstrual cycle has become noticeably irregular — longer gaps, shorter cycles, or skipped periods. Your acne appears to follow some kind of cycle, even if that cycle no longer maps to a regular period. Vasomotor symptoms (hot flushes, night sweats) fluctuate in severity week to week. Your skin seems to improve for a stretch and then flare again without obvious cause.

Patterns more consistent with established postmenopause: You have had no menstrual period for twelve or more consecutive months. Your vasomotor symptoms have stabilised — often less severe than at their peak. Your acne is consistently present without obvious cyclical fluctuation, a low-grade baseline rather than dramatic flares.

Recognising which group you broadly sit in gives you and your clinician a more accurate starting point — and, in many cases, an explanation for why previous approaches may not have worked.

The Early 40s: The Phase That Goes Unnamed

The period from approximately age 40 to 46 occupies an awkward clinical and cultural position. Many women in this age range are experiencing early perimenopausal changes — cycle irregularity, vasomotor symptoms, mood shifts, new or worsening acne — without meeting any formal threshold for a menopausal diagnosis. Some are still ovulating regularly.

Yet the hormonal changes associated with early perimenopause are biologically real and clinically consequential before a woman meets any formal diagnostic criterion.

There is a significant barrier here that goes beyond biology: self-identification. The word “Menopause” — still carries connotations of later life, hot flushes, and a recognisable transition. A 41-year-old woman whose cycle is slightly irregular and who is suddenly breaking out in ways she never did before is unlikely to frame this as a hormonal event related to reproductive ageing. She is more likely to attribute it to stress, to a product change, or to nothing in particular.

Women in their early 40s who seek help for new acne rarely frame the concern in hormonal or perimenopausal terms, even when the presentation is strongly suggestive — in part because both clinical and popular discourse on perimenopause consistently position it as something that happens later.

The consequence is a population of women in their early 40s who may receive acne treatments designed for a different hormonal context, who try and abandon multiple skincare routines without understanding why nothing works, and who are approaching the peak years of perimenopausal acne without an adequate framework for what is driving it.

Knowing that reproductive hormonal shifts can begin driving skin changes years before any formal perimenopausal threshold gives a 41-year-old with new breakouts something she could not have had if nobody named the mechanism: a more accurate way to interpret her own skin.

The clinical implications of the perimenopausal vs. postmenopausal distinction are not merely theoretical. They shape which treatment approaches are likely to be appropriate and why. If you have tried to manage menopausal acne for any length of time, you may already have noticed that what works in one phase stops working — or actively irritates — in another. That is phase mismatch, not product failure.

In Perimenopause

The central challenge is unpredictability. Because the hormonal environment is volatile, no single treatment will perform consistently — your skin is operating under different conditions from one week to the next, and this is the context your choices need to fit, not override.

Strategies that address androgen-driven sebum while simultaneously supporting barrier function tend to hold up better across this range than approaches optimised purely for acne control — because barrier-stripping treatments that work during an androgen-dominant trough can become intolerable within days if estrogen briefly rises and the skin’s behaviour shifts. Whether any specific approach meets your individual skin’s threshold is something that only your skin, observed over time, can answer.

That willingness to adjust — to treat this week’s skin rather than last week’s — is not a sign of having chosen the wrong approach. The unpredictability is in the biology.

In Postmenopause

The challenge shifts from volatility to persistence. The androgenic signal is stable, which means so is the acne — and so is the treatment. Consistency matters more than timing.

The skin is more fragile, however, and this changes how treatments are introduced. The depleted barrier and thinned epidermis of postmenopausal skin tolerate less than they did during perimenopause — not because of personal skin weakness, but because estrogen-mediated processes supporting barrier renewal are no longer active. A treatment tolerated at 47 may provoke persistent irritation at 55. That irritation is not a sign to push through; it is the skin communicating that the pace or concentration exceeds what the current barrier can sustain.

Individual skin response determines whether any active can be sustained at a given concentration and frequency. The evidence supports the principle: effective ingredients introduced gradually, alongside consistent barrier support, give postmenopausal skin the best conditions for tolerating treatment at all.

The role of hormone therapy is potentially more clearly beneficial for skin in postmenopause, where the estrogen deficit is complete and stable — meaning the gap between the current state and an estrogen-supported state is at its widest. The choice of progestogen component, and the route of administration, remain critical considerations.

• Dréno B, Thiboutot D, Layton AM, Berson D, Perez M, Kang S. Large-scale international study enhances understanding of an emerging acne population: adult females. Journal of the European Academy of Dermatology and Venereology. 2015;29(6):1096–1106. DOI: 10.1111/jdv.12757.
• Carmina E, Dreno B, Lucky WA, Agak WG, Dokras A, Kim JJ, Lobo RA, Ramezani Tehrani F, Dumesic D. Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Journal of the Endocrine Society. 2022;6(3):bvac003. DOI: 10.1210/jendso/bvac003.
• Nikoletić ĐC, Ivanov D, Levakov O, Bulajić J, Lukač S, Karan Rakić V, Ivkov-Simić M. Menopause, Menstrual Cycle, and Skin Barrier Function. Skin Research and Technology. 2025;31(7):e70203. DOI: 10.1111/srt.70203.
• Dias da Rocha MA, Saint Aroman M, Mengeaud V, Carballido F, Doat G, Coutinho A, Bagatin E. Unveiling the Nuances of Adult Female Acne: A Comprehensive Exploration of Epidemiology, Treatment Modalities, Dermocosmetics, and the Menopausal Influence. International Journal of Women’s Health. 2024;16:663–678. DOI: 10.2147/IJWH.S431523.
• Ianoşi S, Ianoşi G, Neagoe D, Ionescu O, Zlatian O, Docea AO, Badiu C, Sifaki M, Tsoukalas D, Tsatsakis AM, Spandidos DA, Călina D. Age-dependent endocrine disorders involved in the pathogenesis of refractory acne in women. Molecular Medicine Reports. 2016;14(6):5501–5506. DOI: 10.3892/mmr.2016.5924.
• McConnell DS, Lasley BL, Crawford S, Gee NA, Auchus RJ, SAT-022 Adrenal Androgen Production Is Maintained While Ovarian Estrogens Fall Following the Final Menstrual Period in the Study of Women’s Health Across the Nation (SWAN), Journal of the Endocrine Society, Volume 4, Issue Supplement_1, April-May 2020, SAT–022, https://doi.org/10.1210/jendso/bvaa046.1314
• Parkinson H. Adult and perimenopausal acne and the nurse’s role in management. British Journal of Nursing. 2026;35(3). DOI: 10.12968/bjon.2025.0559.
• Telkkälä A, Sinikumpu S, Huilaja L. Etiology of Adult Female Acne — Systematic Review. Health Science Reports. 2025;8(4):e70697. DOI: 10.1002/hsr2.70697.